Background
As the most prevalent neurological disorder, migraine is
affecting more than 100 million people in Europe [1]
and the USA [2]. Migraine ranks in the top 20 of the
most disabling medical illnesses globally, and has substantial
effects on the quality of life of patients and their
families and on health costs [3]. It has attracted more
and more attention worldwide as a public health issue
because of its high prevalence, frequent attack history,
significant medical burden, and a serious reduction in
quality of life [4].